Executives from five of the country’s largest pharmacy benefit managers will face questions about drug pricing from the U.S. Senate Finance Committee on Tuesday. Over the last decade, these companies have contributed nearly $1 million to the campaigns …
Sorrento Therapeutics alleges in a complaint that billionaire Soon-Shiong kept a cancer drug from making it to market to eliminate a competitor to a drug he invented.
For the second month in a row venture capital fundraising among healthcare startups is down almost 50% year-over-year, but 2019’s first quarter total is the second-highest in the past decade, according to an analysis conducted for Forbes by Pitchbook.
Startups like Eargo and Audicus are trying to break into the market for hearing aids that’s controlled by five manufacturers. Their pitch: lower costs by cutting out audiologists and storefronts, similar to how Warby Parker sells glasses online.
Direct-to-consumer telehealth startup Ro launched in 2017 selling erectile dysfunction pills to men. Now, it’s launching a new brand for women in “midlife” with drugs for treating some of the symptoms of menopause.
Venture capital fundraising among healthcare startups was down on a year-over-year basis in February. But don’t be fooled, startups still raised a lot of money last month.
Maze Therapeutics, a South San Francisco startup, launched with funding from Third Rock Ventures, ARCH Venture Partners, GV and others, with a goal of identifying genetic modifiers to develop new drugs.
Seven pharma executives are expected to face tough questions about the price of their drugs Tuesday before the U.S. Senate Finance Committee. They’ll also be answering to a group that’s received hundreds of thousands of dollars in campaign contribution…